Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients.
Pau RieraBenjamín Rodríguez-SantiagoAdriana LasaLidia Gonzalez-QueredaBerta MartínJuliana SalazarAna SebioAnna C VirgiliJordi MinguillónCristina CampsJordi SurrallesDavid PáezPublished in: Cancers (2020)
This study provides evidence that novel somatic genetic variants along the EGFR-triggered pathway could modulate the response to anti-EGFR drugs in mCRC patients. It also highlights the influence of insulin-related genes and LRIG genes on anti-EGFR efficacy. Our findings could help characterize patients who are resistant to anti-EGFR blockade despite harboring RAS/BRAF wild-type tumors.
Keyphrases
- small cell lung cancer
- end stage renal disease
- epidermal growth factor receptor
- newly diagnosed
- ejection fraction
- chronic kidney disease
- tyrosine kinase
- prognostic factors
- type diabetes
- wild type
- metastatic colorectal cancer
- patient reported outcomes
- metabolic syndrome
- copy number
- weight loss
- dna methylation
- insulin resistance